Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gottlieb: FDA May View State Drug Wholesaler Licensure As Fully Preempted Under DSCSA

Executive Summary

US FDA Commissioner Scott Gottlieb says Congress intended to preempt all state licensure laws that were not identical to federal laws for licensing wholesalers and third-party logistics providers under the Drug Supply Chain Security Act.

You may also be interested in...



FDA's Inaction On Issuing Licensing Rules For Wholesalers and 3PLs Creating Confusion

Highly anticipated proposed rulemaking from the FDA on licensing standards for wholesale distributors and third-party logistics providers has been repeatedly delayed, and the reasons for the delay are unclear. The rule is five years overdue under a DSCSA mandated timeline.

FDA's Draft Track and Trace Guidance Is Too Late As Serialization Systems Are Already In Place - Industry

The pharmaceutical industry sees many problems with US FDA’s draft guidance on product serialization to comply with the Drug Supply Chain Security Act of 2012, including requirements for “absolute uniformity.” Moreover, it’s coming out too late for companies that long ago set up serialization IT systems to comply with a November deadline.

Industry Groups Seek Clarity From FDA On Exception Handling Under DSCSA

As supply chain partners drill down into implementing the last phase of Drug Supply Chain Security Act serialization, they ask FDA for more clarity, and some relief, on exception handling for products with no serial numbers after full track-and-trace goes into effect.

Topics

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel